Alpha7 Nicotinic Receptor Modulators for CNS Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor have limited efficacy and non-specific effects, and struggle to effectively target the central nervous system, leading to adverse effects and suboptimal benefits in treating cognitive disorders and neurodegenerative diseases.
Innovation Solution
Development of new compounds defined by a specific formula [I], which are positive allosteric modulators of the α7 nicotinic acetylcholine receptor, designed to selectively modulate α7 NNRs, enhancing endogenous cholinergic transmission without direct receptor activation, and are formulated for improved therapeutic efficacy and reduced adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor are used, then some therapeutic effect is achieved, but they have limited efficacy and non-specific effects leading to adverse effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific structural features (formula I) that confer selectivity for the α7 nicotinic acetylcholine receptor subtype. The molecular structure includes specific substituents (R1-R6, A7-A9, R7-R11) that are optimized to interact with unique characteristics of the α7 receptor binding site, thereby achieving localized and specific modulation of this receptor subtype while minimizing interactions with other neuronal nicotinic receptors, thus reducing adverse effects associated with non-specific binding
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as substituent types (R1-R6), ring structures (A7-A9), and positional isomers to optimize the balance between therapeutic efficacy and selectivity. By adjusting these chemical parameters, the compounds achieve enhanced potency and specificity for α7 receptors compared to previous PAMs, thereby improving therapeutic outcomes while reducing off-target effects
2Reliability
If current PAMs are used to target the central nervous system, then some cognitive benefits are achieved, but they struggle to effectively target the CNS leading to suboptimal benefits
Solution Approach 1:
The patent applies parameter changes by optimizing molecular properties such as lipophilicity, molecular weight, and structural rigidity within compounds of formula I to enhance blood-brain barrier penetration. Specific substituent combinations and ring structures are selected to achieve optimal physicochemical parameters that facilitate CNS delivery while maintaining α7 receptor selectivity, thereby overcoming the limited CNS targeting capability of previous PAMs
3Reliability
If selective modulation of α7 NNRs is achieved, then therapeutic efficacy is enhanced, but compound design becomes more complex
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core pyridine or pyrimidine ring system (A7-A9), substituent groups (R1-R6) that provide selectivity, and linker regions (R7-R11) that optimize binding interactions. This segmented approach allows systematic optimization of each component for α7 selectivity while providing a modular framework that simplifies the design process compared to de novo development of selective agents
Data Source
AI summary
The present invention relates to compounds of formula (I) useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine a7 receptor.